Vimarsana
Biggest News Aggregation in the World

Page 13 - Company Codes News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Company Codes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Company Codes Today - Breaking & Trending Today

Oncolytics Biotech® Announces Phase 1b Data Demonstrating Clinical Proof-of-Concept for Pelareorep-Proteasome Inhibitor Combination in Multiple Myeloma in an Abstract at the AACR Annual Meeting - Vimarsana News

Oncolytics Biotech® Announces Phase 1b Data Demonstrating Clinical Proof-of-Concept for Pelareorep-Proteasome Inhibitor Combination in Multiple Myeloma in an Abstract at the AACR Annual Meeting

Published: March 10, 2022

Oncolytics Biotech® Announces Phase 1b Data Demonstrating Clinical Proof-of-Concept for Pelareorep-Proteasome Inhibitor Combination in Multiple Myeloma in an Abstract at the AACR Annual Meeting - read this article along with other careers information, tips and advice on BioSpace

Source: biospace.com
Related Topics:
New OrleansUnited StatesNew Orleans Convention CenterKevin KellyJon PattonTimothy MccarthyThomas HeinemanOncolytics Biotech IncUnited States National Cancer InstituteCompany ContactErnestn Morial Convention CenterOrleans Convention CenterAmerican Association For Cancer ResearchCompany CodesOncolytics BiotechSecurities ExchangeBristol Myers SquibbAmerican AssociationCancer ResearchAnnual MeetingConvention CenterAssociate ProfessorClinical MedicineKeck SchoolSouthern California
Antengene Announces XPOVIO® Approved by the TGA in Australia for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Triple Class-Refractory Multiple Myeloma - Vimarsana News

Antengene Announces XPOVIO® Approved by the TGA in Australia for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Triple Class-Refractory Multiple Myeloma

Published: March 9, 2022

Antengene Announces XPOVIO® Approved by the TGA in Australia for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Triple Class-Refractory Multiple Myeloma - read this article along with other careers information, tips and advice on BioSpace

Source: biospace.com
Related Topics:
Hong KongUnited StatesSouth KoreaAndrew SpencerThomas KaralisJay MeiAsia PacificPeter QianCompany AnnualAntengene CorporationDrug AdministrationAustralian Government Department Of HealthHong Kong Stock ExchangeCompany CodesPrnewswire Antengene Corporation LimitedAntengene Corporation LimitedTherapeutic Goods AdministrationCorporation LimitedAustralian Government DepartmentHang QuachProfessor Andrew SpencerAlfred HospitalMyeloma AustraliaPatients BeyondAsia Pacific Region
Vicore strengthens rare lung disease pipeline with PAH indication - Vimarsana News

Vicore strengthens rare lung disease pipeline with PAH indication

Published: March 9, 2022

Vicore strengthens rare lung disease pipeline with PAH indication - read this article along with other careers information, tips and advice on BioSpace

Source: biospace.com
Related Topics:
United KingdomCity OfVastra Gotalands LanVicore PharmaGerry CoghlanChris DentonCarl Johan DalsgaardUniversity College LondonCompany CodesRoyal Free National Pulmonary Hypertension ServiceNational Pulmonary Hypertension Physicians AssociationVicore Pharma HoldingCentre For RheumatologyProfessor Chris DentonJoint DirectorRoyal Free HospitalRoyal FreeUniversity CollegeJohan DalsgaardPharma HoldingIcore Strengthens Rare Lung Disease Pipeline With Pah Indication
Eisai initiates submission of application data of lecanemab under the prior assessment consultation system in Japan with the aim of an earlier regulatory approval - Vimarsana News

Eisai initiates submission of application data of lecanemab under the prior assessment consultation system in Japan with the aim of an earlier regulatory approval

Published: March 5, 2022

Eisai initiates submission of application data of lecanemab under the prior assessment consultation system in Japan with the aim of an earlier regulatory approval - read this article along with other careers information, tips and advice on BioSpace

Source: biospace.com
Related Topics:
Uppsala LanOskar BossonParkinson AbbvieGunilla OsswaldUppsala UniversityVp CommunicationsNational Institutes Of HealthNational Institute OnMinistry Of HealthDrug AdministrationCompany CodesDevices AgencyAlzheimer Clinical Trial ConsortiumNasdaq StockholmMedical Devices AgencyBiologics License ApplicationAccelerated ApprovalClinical Trial ConsortiumNational InstituteNational InstitutesBreakthrough TherapyCommercialization AgreementNasdaq Stockholm Mid CapIsai Initiates Submission Of Application Data Lecanemab Under The Prior Assessment Consultation System In Japan With Aim An Earlier Regulatory Approval
Antengene Announces XPOVIO® Regulatory Approval in Singapore for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Three Indications - Vimarsana News

Antengene Announces XPOVIO® Regulatory Approval in Singapore for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Three Indications

Published: March 2, 2022

Antengene Announces XPOVIO® Regulatory Approval in Singapore for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Three Indications - read this article along with other careers information, tips and advice on BioSpace

Source: biospace.com
Related Topics:
Hong KongSouth KoreaThomas KaralisJay MeiAsia PacificPeter QianKaryopharm Therapeutics IncCompany AnnualAntengene CorporationDrug AdministrationSelective Inhibitor Of NuclearHealth Sciences AuthorityHong Kong Stock ExchangeCompany CodesPrnewswire Antengene Corporation LimitedAntengene Corporation LimitedCorporation LimitedSelective InhibitorNuclear ExportKaryopharm TherapeuticsPatients BeyondAsia Pacific RegionGreater ChinaAnnual ReportHong Kong Stock